Vivek Yedavalli

Dr. Vivek Yedavalli

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Clinical Imaging
Verified
Journal Article
Closed access
VYVivek Yedavalli
Vivek Yedavalli
ETElizabeth Tong
Elizabeth Tong
DMDann Martin
Dann Martin
KYKristen W. Yeom
Kristen W. Yeom
NFNils Daniel Forkert
Nils Daniel Forkert

1 June 2022 in Journal Of Neuroradiology
Verified
Journal Article
Closed access
OSOmid Shafaat
Omid Shafaat
JBJoshua Bernstock
Joshua Bernstock
ASAmir Shafaat
Amir Shafaat
VYVivek Yedavalli
Vivek Yedavalli
GEGalal Elsayed
Galal Elsayed
HSHouman Sotoudeh
Houman Sotoudeh

7 April 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
SRSana Rehman
Sana Rehman
ANArsalan Nadeem
Arsalan Nadeem
UAUmar Akram
Umar Akram
ASAbeer Sarwar
Abeer Sarwar
AQAmmara Quraishi
Ammara Quraishi
VYVivek Yedavalli
Vivek Yedavalli
Ischemic stroke poses a significant global health challenge, necessitating ongoing exploration of its pathophysiology and treatment strategies. This comprehensive review integrates various aspects of ischemic stroke research, emphasizing crucial mechanisms, therapeutic approaches, and the role of clinical imaging in disease management. It discusses the multifaceted role of Netrin-1, highlighting its potential in promoting neurovascular repair and mitigating post-stroke neurological decline. It also examines the impact of blood–brain barrier permeability on stroke outcomes and explores alternative therapeutic targets such as statins and sphingosine-1-phosphate signaling. Neurocardiology investigations underscore the contribution of cardiac factors to post-stroke mortality, emphasizing the importance of understanding the brain–heart axis for targeted interventions. Additionally, the review advocates for early reperfusion and neuroprotective agents to counter-time-dependent excitotoxicity and inflammation, aiming to preserve tissue viability. Advanced imaging techniques, including DWI, PI, and MR angiography, are discussed for their role in evaluating ischemic penumbra evolution and guiding therapeutic decisions. By integrating molecular insights with imaging modalities, this interdisciplinary approach enhances our understanding of ischemic stroke and offers promising avenues for future research and clinical interventions to improve patient outcomes.

17 May 2017 in Journal of Neuroimaging
Verified
Journal Article
Closed access
PDF file
VYVivek Yedavalli
Vivek Yedavalli
SSSteffen Sammet
Steffen Sammet

28 December 2023 in Clinical Neuroradiology
Verified
Journal Article
Closed access
PDF file
VYVivek Yedavalli
Vivek Yedavalli
MKManisha Koneru
Manisha Koneru
OHOmar Hamam
Omar Hamam
MHMeisam Hoseinyazdi
Meisam Hoseinyazdi
EMElisabeth Breese Marsh
Elisabeth Breese Marsh
AHArgye Hillis
Argye Hillis

23 July 2024 in Journal of Neurology, Neurosurgery & Psychiatry
Verified
Journal Article
Closed access
PDF file
Hamza A SalimHamza A Salim
Hamza A Salim
VYVivek Yedavalli
Vivek Yedavalli
BMBasel Musmar
Basel Musmar
NANimer Adeeb
Nimer Adeeb
KNKareem E L Naamani
Kareem E L Naamani
Adam DmytriwAdam Dmytriw
Adam Dmytriw
Background The efficacy of endovascular treatment (EVT) in acute ischaemic stroke due to distal medium vessel occlusion (DMVO) remains uncertain. Our study aimed to evaluate the safety and efficacy of EVT compared with the best medical management (BMM) in DMVO. Methods In this prospectively collected, retrospectively reviewed, multicentre cohort study, we analysed data from the Multicentre Analysis of primary Distal medium vessel occlusions: effect of Mechanical Thrombectomy registry. Patients with acute ischaemic stroke due to DMVO in the M2, M3 and M4 segments who underwent EVT or received BMM were included. Primary outcome measures comprised 10 co-primary endpoints, including functional independence (mRS 0–2), excellent outcome (mRS 0–1), mortality (mRS 6) and haemorrhagic complications. Propensity score matching was employed to balance the cohorts. Results Among 2125 patients included in the primary analysis, 1713 received EVT and 412 received BMM. After propensity score matching, each group comprised 391 patients. At 90 days, no significant difference was observed in achieving mRS 0–2 between EVT and BMM (adjusted OR 1.00, 95% CI 0.67 to 1.50, p>0.99). However, EVT was associated with higher rates of symptomatic intracerebral haemorrhage (8.4% vs 3.0%, adjusted OR 3.56, 95% CI 1.69 to 7.48, p<0.001) and any intracranial haemorrhage (37% vs 19%, adjusted OR 2.61, 95% CI 1.81 to 3.78, p<0.001). Mortality rates were similar between groups (13% in both, adjusted OR 1.48, 95% CI 0.87 to 2.51, p=0.15). Conclusion Our findings suggest that while EVT does not significantly improve functional outcomes compared with BMM in DMVO, it is associated with higher risks of haemorrhagic complications. These results support a cautious approach to the use of EVT in DMVO and highlight the need for further prospective randomised trials to refine treatment strategies.